Features | Partner Sites | Information | LinkXpress
Sign In
SEEGENE
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Test Being Developed to Diagnose Mild Cognitive Impairment

By Labmedica International staff writers
Posted on 18 Feb 2013
Autoantibody biomarkers in the blood can potentially be used to diagnose early stages of Alzheimer's and Parkinson's diseases.

A grant of USD 799,800 from the Osteopathic Heritage Foundation at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (Stratford, NJ, USA) will help expand earlier research conducted by Robert Nagele, PhD, director of the Biomarker Discovery Center (at the University). Dr. Nagele's published research includes recent findings that identify specific autoantibody biomarkers in the blood for early diagnosis of Alzheimer's and Parkinson's diseases.

The funded project will pursue three specific goals: to identify a small number of autoantibody biomarkers that can accurately (90% or higher) diagnose MCI cases caused by early stage Alzheimer's disease; to verify the accuracy rate with a larger scale study; and to construct and test a diagnostic kit that is maximally accurate for the broadest possible MCI patient population. If successful, the study will then apply for final US Food and Drug Administration (FDA; Silver Spring, MD, USA) approval of the test.

"Using our novel biomarker discovery strategy, we have shown that it is possible to use a single drop of blood to diagnose Alzheimer's and Parkinson's with greater than 95% accuracy," said Dr Nagele. "This same approach should also allow us to identify a small number of biomarkers that can also accurately diagnose MCI caused by early-stage Alzheimer's disease."

Current approaches to MCI diagnosis rely on physical, neurological, and psychiatric examinations, laboratory tests, and a thorough review of the patient's medications and medical history. Recently, great attention has been given to using neuroimaging technologies to detect structural changes in the brain before symptoms appear. However, these approaches require expensive equipment and technology and can require hospital visits, the injection of radioactive compounds, and the availability of radiologists with advanced training in these techniques.

While current treatments for Alzheimer's cannot stop the progression of the disease, several medications are capable of significantly enhancing brain performance and alleviating symptoms. A number of promising drugs are also currently under development and in clinical trials for the treatment of early Alzheimer's disease. An easy-to-administer blood test for MCI would give pharmaceutical companies a way to identify patients for clinical trials who are at a very early stage of their disease and give researchers a nearly immediate way to monitor the effectiveness of medications under examination.

Related Links:

University of Medicine and Dentistry of New Jersey
US Food and Drug Administration



ADVANCED INSTRUMENTS
GREINER-BIO-ONE
PURITAN MEDICAL
BioConferenceLive

Channels

Clinical Chemistry

view channel
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).

Pregnancy Tests Evaluated During Early Gravidity

The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.... Read more

Genetic Tests

view channel
Image: The Quant-iT PicoGreen dsDNA Assay Kit (Photo courtesy of Invitrogen).

Blood Test Provides Rapid Method of Detecting Solid Cancers

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing detection methods have insufficient sensitivity or patient coverage for broad clinical applicability.... Read more

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Pathology

view channel
Image: Immunostaining of human lung tissue, fixed with HOPE, from a patients suffering from legionnaire\'s disease. One legionella protein (red-brown), the bacteria-containing vacuoles and individual legionella inside the scavenger cells can be detected. The infection process can be observed immediately using proteomics (Photo courtesy of Braunschweig University of Technology).

Novel Method Prepares Tissue Samples for Analyzing Proteins

A new way of preparing patient tissue for analyses might soon become the new standard, possibly replacing tissues fixed with formalin, before they are embedded in wax-like paraffin and cut into razor-thin slices.... Read more

Industry News

view channel

Roche and Hitachi Renew Alliance in Diagnostics

Roche (Basel, Switzerland) and Hitachi (Tokyo, Japan) have renewed their alliance in the diagnostics business by 10-years for the joint development and manufacture of the next generation of instruments and workflow automation solutions for medical laboratories. The renewed alliance marks a significant milestone towards... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.